The Effectiveness of Sofosbuvir and Daclatasvir in the Treatment of Hepatitis C in Thalassaemia Major Patients and their Effect on Haematological Factors

被引:0
作者
Zamani, Farhad [1 ]
Ajdarkosh, Hossein [1 ]
Safarnezhad-Tameshkel, Fahimeh [1 ]
Azarkeivan, Azita [2 ]
Keyvani, Hossein [1 ]
Naserifar, Farshad [1 ]
Vafaeimanesh, Jamshid [1 ,3 ]
机构
[1] Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Tehran, Iran
[2] Blood Transfus Res Ctr, High Inst Res & Educ Transfus Med, Thalassemia Clin, Pediat Hematol Oncol, Tehran, Iran
[3] Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom, Iran
关键词
Anaemia; daclatasvir; hepatitis C virus; sofosbuvir; thalassaemia major; ADVANCED LIVER-DISEASE; HCV GENOTYPE 1; VIRUS-INFECTION; PHASE-III; RIBAVIRIN; LEDIPASVIR; COMBINATION; PREVALENCE; CIRRHOSIS; NAIVE;
D O I
10.4103/ijmm.IJMM_18_90
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Context: Patients with thalassaemia arc at risk of infections such as hepatitis C virus (HCV) due to their repeated blood transfusions; meanwhile, the treatment of thalassaemia patients who had developed HCV infection is a controversial issue. Aims: Although the effectiveness of direct-acting anti virals on HCV infection has been confirmed, their side-effects as well as effects on haematological factors due to the resultant need for blood transfusion remain to be further understood. Materials and Methods: In this study, 61 patients with major beta thalassaemia and HCV infection, and who had a history of interferon treatment failure were examined. The patients underwent a 24-week treatment with sofosbuvir (SOF) and daclatasvir (DAC). Sustained virological response 12 was used to assess response to treatment. At the end of the study, the need for blood transfusion and serum terrain was evaluated. Results: About 98.4% of the patients responded to the treatment, and only one patient with genotype 1b did not respond positively. No significant complications necessitating treatment cessation were observed, and all the patients tolerated the treatment well. The level of liver enzymes showed a significant reduction 12 weeks after the treatment. The need for blood transfusions in patients before treatment was averagely 1.595 +/- 0.65 bag per month, in which 1.593 +/- 0.64 bags were received after treatment (P = 0.9). This regimen did not affect the amount of anaemia in patients and did not differentiate the need for blood transfusions. The rate of haemoglobin before treatment was 9.5 +/- 1.42 g/dl, which reached 9.6 +/- 1.6 g/dl after treatment (P = 0.54). Ferritin levels decreased significantly (from 1948.08 +/- 1539.54 to 1315.73 +/- 1207.67 ng/ml) (P = 0.001) in the patients after the treatment. Conclusion: Combination of SOF and DAC is an effective and tolerable treatment regimen without affect on the amount of anaemia in patients and did not differentiate the need for blood transfusions.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 50 条
  • [41] Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study
    Akhil, Mohammed Shujauddin
    Kirushnan, Balaji
    Martin, Melvin
    Arumugam, Kanakaraj
    Prasad, N. K. Ganesh
    Ravichandran, Rajan
    NEPHROLOGY, 2018, 23 (05) : 446 - 452
  • [42] Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
    Mohamed, Hala
    Abd El Ghany, Weal
    Yehia, Reem
    Fouad, Magdy
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 8 (01) : 36 - 41
  • [43] Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison
    Swallow, Elyse
    Song, Jinlin
    Yuan, Yong
    Kalsekar, Anupama
    Kelley, Caroline
    Peeples, Miranda
    Mu, Fan
    Ackerman, Peter
    Signorovitch, James
    CLINICAL THERAPEUTICS, 2016, 38 (02) : 404 - 412
  • [44] The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK
    McEwan, Phil
    Bennett, Hayley
    Ward, Thomas
    Webster, Samantha
    Gordon, Jason
    Kalsekar, Anupama
    Yuan, Yong
    Brenner, Michael
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 28 (02) : 173 - 180
  • [45] Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
    Leleu, H.
    Blachier, M.
    Rosa, I.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (04) : 376 - 383
  • [46] The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease
    Young, Jim
    Weis, Nina
    Hofer, Harald
    Irving, William
    Weiland, Ola
    Giostra, Emiliano
    Manuel Pascasio, Juan
    Castells, Lluis
    Prieto, Martin
    Postema, Roelien
    Lefevre, Cinira
    Evans, David
    Bucher, Heiner C.
    Luis Calleja, Jose
    BMC INFECTIOUS DISEASES, 2017, 17
  • [47] Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C
    Wuerth, Kelli
    Magel, Tianna
    Conway, Brian
    FUTURE VIROLOGY, 2019, 14 (11) : 715 - 727
  • [48] Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients
    Jain, Ayush
    Kalra, Bhupinder Singh
    Srivastava, Siddharth
    Chawla, Shalini
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2019, 38 (01) : 39 - 43
  • [49] Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection
    Sundaram, Vinay
    Kowdley, Kris V.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (01) : 13 - 20
  • [50] Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation
    Aly, Osama Aboelfotoh
    Yousry, Wael Ahmed
    Teama, Nahla Mohamed
    Shona, Eman Mohammed
    ElGhandour, Ahmed Mohamed
    EGYPTIAN LIVER JOURNAL, 2020, 10 (01)